{"record":{"leader":"cx  r22     2  45","datafield":[{"ind2":" ","ind1":" ","subfield":{"code":"a","content":"20171020afrey50      ba0"},"tag":100},{"ind2":" ","ind1":" ","subfield":[{"code":"a","content":"fre"},{"code":2,"content":"639-2"}],"tag":101},{"ind2":" ","ind1":" ","subfield":{"code":"a","content":2014},"tag":103},{"ind2":" ","ind1":" ","subfield":[{"code":"a","content":"k"},{"code":"f","content":"fre"}],"tag":104},{"ind2":" ","ind1":" ","subfield":[{"code":"a","content":0},{"code":"b","content":"#"},{"code":"c","content":"#"}],"tag":106},{"ind2":" ","ind1":" ","subfield":{"code":"a","content":"AFNOR"},"tag":152},{"ind2":" ","ind1":" ","subfield":{"code":"a","content":"Oeuvre Textuelle"},"tag":189},{"ind2":" ","ind1":" ","subfield":[{"code":7,"content":"ba0yba0"},{"code":"t","content":"Sclérose en plaques et innovations thérapeutiques, place de la Fampridine"}],"tag":241},{"ind2":" ","ind1":" ","subfield":[{"code":7,"content":"ba0yba0y"},{"code":"a","content":"La Sclérose en plaques est une pathologie chronique du système nerveux central. Elle est caractérisée par l\u2019attaque et la destruction de la gaine de myéline protégeant les fibres nerveuses, conduisant à plus ou moins long terme à un handicap fonctionnel irréversible. Depuis l\u2019apparition du premier immunomodulateur par voie injectable dans les années 1990, l\u2019arsenal thérapeutique dans la SEP ne cesse de s\u2019enrichir, avec notamment l\u2019apparition ces dernières années de nouvelles thérapies par voie orale qui vont, à terme, probablement modifier la stratégie thérapeutique. Une nouvelle molécule à visée symptomatique a également vu le jour récemment : Fampridine (FAMPYRA®), avec pour objectif une amélioration des troubles de la marche, dont souffre une grande partie des patients atteints de SEP. Ce traitement s\u2019inscrit dans un programme global de rééducation adapté mais ne se substitue pas à un tel programme. Une plaquette d\u2019information destinée au patient lui explique de façon simple son traitement par Fampridine, et répond aux potentielles questions qu\u2019il pourrait se poser à propos de celui-ci."}],"tag":300},{"ind2":0,"ind1":" ","subfield":[{"code":"b","content":"Thèse d'exercice"},{"code":"c","content":"Pharmacie"},{"code":"e","content":"Lille 2"},{"code":"d","content":2014}],"tag":328},{"ind2":1,"ind1":" ","subfield":[{"code":3,"content":178445177},{"code":7,"content":"ba0yba07"},{"code":"a","content":"Burette"},{"code":"b","content":"Clémence"},{"code":"f","content":"1990-...."},{"code":4,"content":"070"}],"tag":501},{"ind2":1,"ind1":" ","subfield":[{"code":3,"content":"078620791"},{"code":7,"content":"ba0yba07"},{"code":"a","content":"Frimat"},{"code":"b","content":"Bruno"},{"code":"f","content":"1967-...."},{"code":4,"content":727}],"tag":501},{"ind2":2,"ind1":0,"subfield":[{"code":3,"content":"026404389"},{"code":7,"content":"ba0yba07"},{"code":"a","content":"Université du droit et de la santé"},{"code":"c","content":"Lille"},{"code":"c","content":"1969-2017"},{"code":4,"content":295}],"tag":511},{"ind2":" ","ind1":" ","subfield":[{"code":3,"content":"027315010"},{"code":"a","content":"Sclérose en plaques"},{"code":3,"content":"027589838"},{"code":"x","content":"Thérapeutique"},{"code":2,"content":"rameau"}],"tag":606},{"ind2":" ","ind1":" ","subfield":[{"code":3,"content":"040743306"},{"code":"a","content":"Sclérose en plaques"},{"code":3,"content":"038961334"},{"code":"x","content":"traitement médicamenteux"},{"code":3,"content":"040839486"},{"code":"x","content":"Dissertation universitaire"},{"code":2,"content":"fmesh"}],"tag":606},{"ind2":" ","ind1":" ","subfield":[{"code":3,"content":"040807126"},{"code":"a","content":"4-Amino-pyridine"},{"code":3,"content":"038961784"},{"code":"x","content":"usage thérapeutique"},{"code":3,"content":"040839486"},{"code":"x","content":"Dissertation universitaire"},{"code":2,"content":"fmesh"}],"tag":606},{"ind2":" ","ind1":" ","subfield":[{"code":7,"content":"ba0yba0"},{"code":3,"content":"027253139"},{"code":"a","content":"Thèses et écrits académiques"},{"code":2,"content":"rameau"}],"tag":608},{"ind2":" ","ind1":0,"subfield":[{"code":"a","content":"Sclérose en plaques"},{"code":"a","content":"immunopathologie"},{"code":"a","content":"traitements actuels"},{"code":"a","content":"innovations thérapeutiques"},{"code":"a","content":"stratégie thérapeutique"},{"code":"a","content":"Fampridine"}],"tag":610},{"ind2":3,"ind1":" ","subfield":[{"code":"a","content":"FR"},{"code":"b","content":"Abes"},{"code":"c","content":20241127},{"code":"g","content":"AFNOR"}],"tag":801}],"controlfield":[{"tag":"001","content":206333889},{"tag":"003","content":"http://www.idref.fr/206333889"},{"tag":"004","content":20171020},{"tag":"005","content":20241127071437},{"tag":"006","content":"0499"},{"tag":"007","content":"0499"},{"tag":"008","content":"Tr2"}]}}